Insider · CIK 0001340097

Invus Public Equities, L.P.

CIK 0001340097 Name as filed on the most recent filing

Filed as Invus Public Equities, L.P. (38)

70 transaction lines · from 38 filings · filed 2012-10-25 to 2024-12-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2024-12-10 S, Open-market sale Scholar Rock Holding CorpSRRK 66,640,000, disposed Open Form 4 filing 0000950170-24-135847
2024-11-25 S, Open-market sale Scholar Rock Holding CorpSRRK 5 lines 15,757,639, disposed Open Form 4 filing 0000950170-24-131539
2024-08-08 S, Open-market sale Glycomimetics IncGLYC 50,009, disposed Open Form 4 filing 0000950170-24-094800
2024-08-07 S, Open-market sale Glycomimetics IncGLYC 11,197, disposed Open Form 4 filing 0000950170-24-094800
2024-08-06 S, Open-market sale Glycomimetics IncGLYC 10,188, disposed Open Form 4 filing 0000950170-24-092864
2024-08-05 S, Open-market sale Glycomimetics IncGLYC 30,996, disposed Open Form 4 filing 0000950170-24-092864
2024-08-02 S, Open-market sale Glycomimetics IncGLYC 57,354, disposed Open Form 4 filing 0000950170-24-090910
2024-08-01 S, Open-market sale Glycomimetics IncGLYC 13,743, disposed Open Form 4 filing 0000950170-24-090910
2024-07-30 S, Open-market sale Glycomimetics IncGLYC 167,185, disposed Open Form 4 filing 0000950170-24-088020
2024-07-29 S, Open-market sale Glycomimetics IncGLYC 85,637, disposed Open Form 4 filing 0000950170-24-088020
2024-07-26 S, Open-market sale Glycomimetics IncGLYC 62,440, disposed Open Form 4 filing 0000950170-24-088020
2023-10-12 P, Open-market purchase Scholar Rock Holding CorpSRRK 2 lines 15,086,736, acquired Open Form 4 filing 0000950170-23-053600
2023-06-05 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 72,215,130, acquired Open Form 4 filing 0000899243-23-014464
2023-04-28 P, Open-market purchase Scholar Rock Holding CorpSRRK 202,845, acquired Open Form 4 filing 0000899243-23-012043
2023-02-24 P, Open-market purchase Glycomimetics IncGLYC 170,000, acquired Open Form 4 filing 0000899243-23-006426
2023-02-23 P, Open-market purchase Glycomimetics IncGLYC 350,760, acquired Open Form 4 filing 0000899243-23-006027
2023-02-22 P, Open-market purchase Glycomimetics IncGLYC 268,995, acquired Open Form 4 filing 0000899243-23-006027
2023-02-21 P, Open-market purchase Glycomimetics IncGLYC 92,500, acquired Open Form 4 filing 0000899243-23-006027
2023-02-17 P, Open-market purchase Glycomimetics IncGLYC 341,000, acquired Open Form 4 filing 0000899243-23-005502
2023-02-16 P, Open-market purchase Glycomimetics IncGLYC 531,129, acquired Open Form 4 filing 0000899243-23-005502
2023-02-15 P, Open-market purchase Glycomimetics IncGLYC 2,155,800, acquired Open Form 4 filing 0000899243-23-005502
2023-02-09 P, Open-market purchase Glycomimetics IncGLYC 37,123, acquired Open Form 4 filing 0000899243-23-004819
2023-01-09 S, Open-market sale Scholar Rock Holding CorpSRRK 10,373, disposed Open Form 4 filing 0000899243-23-001634
2023-01-05 P, Open-market purchase Scholar Rock Holding CorpSRRK 455,091, acquired Open Form 4 filing 0000899243-23-001307
2022-10-25 P, Open-market purchase Scholar Rock Holding CorpSRRK 1,047,383, acquired Open Form 4 filing 0000899243-22-034318
2022-10-04 P, Open-market purchase Scholar Rock Holding CorpSRRK 520,760, acquired Open Form 4 filing 0000899243-22-033263
2022-10-03 P, Open-market purchase Scholar Rock Holding CorpSRRK 238,789, acquired Open Form 4 filing 0000899243-22-033263
2022-08-05 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 6,065,175, acquired Open Form 4 filing 0000899243-22-028108
2022-08-01 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 40,434,500, acquired Open Form 4 filing 0000899243-22-027156
2021-08-03 P, Open-market purchase Omega Therapeutics, Inc.OMGA 14,875,000, acquired Open Form 4 filing 0000899243-21-031304
2021-07-30 P, Open-market purchase Omega Therapeutics, Inc.OMGA 1,210,343, acquired Open Form 4 filing 0000899243-21-031304
2021-02-01 S, Open-market sale Seer, Inc.SEER 16,201,519, disposed Open Form 4 filing 0000899243-21-004899
2020-12-16 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 35,000,000, acquired Open Form 4 filing 0000899243-20-034268
2020-12-08 P, Open-market purchase Seer, Inc.SEER 15,010,000, acquired Open Form 4 filing 0001628280-20-017346
2020-11-03 P, Open-market purchase SQZ Biotechnologies CoSQZ 7,440,000, acquired Open Form 4 filing 0000899243-20-030316
2020-06-16 P, Open-market purchase Generation Bio Co.GBIO 15,200,000, acquired Open Form 4 filing 0000899243-20-017117
2018-06-28 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 718,935, acquired Open Form 4 filing 0000899243-18-018727
2018-06-27 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 1,568,442, acquired Open Form 4 filing 0000899243-18-018727
2018-06-25 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 2,955,083, acquired Open Form 4 filing 0000899243-18-018161
2018-06-22 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 340,090, acquired Open Form 4 filing 0000899243-18-018161
2018-06-21 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 684,613, acquired Open Form 4 filing 0000899243-18-017617
2018-06-20 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 164,613, acquired Open Form 4 filing 0000899243-18-017617
2018-06-19 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 120,819, acquired Open Form 4 filing 0000899243-18-017617
2018-06-18 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 477,937, acquired Open Form 4 filing 0000899243-18-017071
2018-06-14 P, Open-market purchase Lexicon Pharmaceuticals, Inc.LXRX 116,462, acquired Open Form 4 filing 0000899243-18-017071

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Invus Public Equities, L.P., insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001340097

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.